Cargando…

Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge

BACKGROUND: Induction of broadly neutralizing antibodies, such as the monoclonal antibodies IgGb12, 2F5 and 2G12, is the objective of most antibody-based HIV-1 vaccine undertakings. However, despite the relative conserved nature of epitopes targeted by these antibodies, mechanisms underlying the sen...

Descripción completa

Detalles Bibliográficos
Autores principales: Borggren, Marie, Repits, Johanna, Sterjovski, Jasminka, Uchtenhagen, Hannes, Churchill, Melissa J., Karlsson, Anders, Albert, Jan, Achour, Adnane, Gorry, Paul R., Fenyö, Eva Maria, Jansson, Marianne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116816/
https://www.ncbi.nlm.nih.gov/pubmed/21698221
http://dx.doi.org/10.1371/journal.pone.0020135
_version_ 1782206280367079424
author Borggren, Marie
Repits, Johanna
Sterjovski, Jasminka
Uchtenhagen, Hannes
Churchill, Melissa J.
Karlsson, Anders
Albert, Jan
Achour, Adnane
Gorry, Paul R.
Fenyö, Eva Maria
Jansson, Marianne
author_facet Borggren, Marie
Repits, Johanna
Sterjovski, Jasminka
Uchtenhagen, Hannes
Churchill, Melissa J.
Karlsson, Anders
Albert, Jan
Achour, Adnane
Gorry, Paul R.
Fenyö, Eva Maria
Jansson, Marianne
author_sort Borggren, Marie
collection PubMed
description BACKGROUND: Induction of broadly neutralizing antibodies, such as the monoclonal antibodies IgGb12, 2F5 and 2G12, is the objective of most antibody-based HIV-1 vaccine undertakings. However, despite the relative conserved nature of epitopes targeted by these antibodies, mechanisms underlying the sensitivity of circulating HIV-1 variants to broadly neutralizing antibodies are not fully understood. Here we have studied sensitivity to broadly neutralizing antibodies of HIV-1 variants that emerge during disease progression in relation to molecular alterations in the viral envelope glycoproteins (Env), using a panel of primary R5 HIV-1 isolates sequentially obtained before and after AIDS onset. PRINCIPAL FINDINGS: HIV-1 R5 isolates obtained at end-stage disease, after AIDS onset, were found to be more sensitive to neutralization by TriMab, an equimolar mix of the IgGb12, 2F5 and 2G12 antibodies, than R5 isolates from the chronic phase. The increased sensitivity correlated with low CD4(+) T cell count at time of virus isolation and augmented viral infectivity. Subsequent sequence analysis of multiple env clones derived from the R5 HIV-1 isolates revealed that, concomitant with increased TriMab neutralization sensitivity, end-stage R5 variants displayed envelope glycoproteins (Envs) with reduced numbers of potential N-linked glycosylation sites (PNGS), in addition to increased positive surface charge. These molecular changes in Env also correlated to sensitivity to neutralization by the individual 2G12 monoclonal antibody (mAb). Furthermore, results from molecular modeling suggested that the PNGS lost at end-stage disease locate in the proximity to the 2G12 epitope. CONCLUSIONS: Our study suggests that R5 HIV-1 variants with increased sensitivity to broadly neutralizing antibodies, including the 2G12 mAb, may emerge in an opportunistic manner during severe immunodeficiency as a consequence of adaptive molecular Env changes, including loss of glycosylation and gain of positive charge.
format Online
Article
Text
id pubmed-3116816
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31168162011-06-22 Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge Borggren, Marie Repits, Johanna Sterjovski, Jasminka Uchtenhagen, Hannes Churchill, Melissa J. Karlsson, Anders Albert, Jan Achour, Adnane Gorry, Paul R. Fenyö, Eva Maria Jansson, Marianne PLoS One Research Article BACKGROUND: Induction of broadly neutralizing antibodies, such as the monoclonal antibodies IgGb12, 2F5 and 2G12, is the objective of most antibody-based HIV-1 vaccine undertakings. However, despite the relative conserved nature of epitopes targeted by these antibodies, mechanisms underlying the sensitivity of circulating HIV-1 variants to broadly neutralizing antibodies are not fully understood. Here we have studied sensitivity to broadly neutralizing antibodies of HIV-1 variants that emerge during disease progression in relation to molecular alterations in the viral envelope glycoproteins (Env), using a panel of primary R5 HIV-1 isolates sequentially obtained before and after AIDS onset. PRINCIPAL FINDINGS: HIV-1 R5 isolates obtained at end-stage disease, after AIDS onset, were found to be more sensitive to neutralization by TriMab, an equimolar mix of the IgGb12, 2F5 and 2G12 antibodies, than R5 isolates from the chronic phase. The increased sensitivity correlated with low CD4(+) T cell count at time of virus isolation and augmented viral infectivity. Subsequent sequence analysis of multiple env clones derived from the R5 HIV-1 isolates revealed that, concomitant with increased TriMab neutralization sensitivity, end-stage R5 variants displayed envelope glycoproteins (Envs) with reduced numbers of potential N-linked glycosylation sites (PNGS), in addition to increased positive surface charge. These molecular changes in Env also correlated to sensitivity to neutralization by the individual 2G12 monoclonal antibody (mAb). Furthermore, results from molecular modeling suggested that the PNGS lost at end-stage disease locate in the proximity to the 2G12 epitope. CONCLUSIONS: Our study suggests that R5 HIV-1 variants with increased sensitivity to broadly neutralizing antibodies, including the 2G12 mAb, may emerge in an opportunistic manner during severe immunodeficiency as a consequence of adaptive molecular Env changes, including loss of glycosylation and gain of positive charge. Public Library of Science 2011-06-16 /pmc/articles/PMC3116816/ /pubmed/21698221 http://dx.doi.org/10.1371/journal.pone.0020135 Text en Borggren et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Borggren, Marie
Repits, Johanna
Sterjovski, Jasminka
Uchtenhagen, Hannes
Churchill, Melissa J.
Karlsson, Anders
Albert, Jan
Achour, Adnane
Gorry, Paul R.
Fenyö, Eva Maria
Jansson, Marianne
Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge
title Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge
title_full Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge
title_fullStr Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge
title_full_unstemmed Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge
title_short Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge
title_sort increased sensitivity to broadly neutralizing antibodies of end-stage disease r5 hiv-1 correlates with evolution in env glycosylation and charge
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116816/
https://www.ncbi.nlm.nih.gov/pubmed/21698221
http://dx.doi.org/10.1371/journal.pone.0020135
work_keys_str_mv AT borggrenmarie increasedsensitivitytobroadlyneutralizingantibodiesofendstagediseaser5hiv1correlateswithevolutioninenvglycosylationandcharge
AT repitsjohanna increasedsensitivitytobroadlyneutralizingantibodiesofendstagediseaser5hiv1correlateswithevolutioninenvglycosylationandcharge
AT sterjovskijasminka increasedsensitivitytobroadlyneutralizingantibodiesofendstagediseaser5hiv1correlateswithevolutioninenvglycosylationandcharge
AT uchtenhagenhannes increasedsensitivitytobroadlyneutralizingantibodiesofendstagediseaser5hiv1correlateswithevolutioninenvglycosylationandcharge
AT churchillmelissaj increasedsensitivitytobroadlyneutralizingantibodiesofendstagediseaser5hiv1correlateswithevolutioninenvglycosylationandcharge
AT karlssonanders increasedsensitivitytobroadlyneutralizingantibodiesofendstagediseaser5hiv1correlateswithevolutioninenvglycosylationandcharge
AT albertjan increasedsensitivitytobroadlyneutralizingantibodiesofendstagediseaser5hiv1correlateswithevolutioninenvglycosylationandcharge
AT achouradnane increasedsensitivitytobroadlyneutralizingantibodiesofendstagediseaser5hiv1correlateswithevolutioninenvglycosylationandcharge
AT gorrypaulr increasedsensitivitytobroadlyneutralizingantibodiesofendstagediseaser5hiv1correlateswithevolutioninenvglycosylationandcharge
AT fenyoevamaria increasedsensitivitytobroadlyneutralizingantibodiesofendstagediseaser5hiv1correlateswithevolutioninenvglycosylationandcharge
AT janssonmarianne increasedsensitivitytobroadlyneutralizingantibodiesofendstagediseaser5hiv1correlateswithevolutioninenvglycosylationandcharge